Autori
M Chiumente, V Damuzzo, L Agnoletto, L Leonardi, D Mengato

Topic
Analisi statistiche e metanalisi

Rivista
International journal of clinical pharmacology and therapeutics

Impact factor
6,565

Abstract
In general, when equivalence or non-inferiority is investigated for two agents aimed at the same clinical indication, demonstrating the proof of no difference or noninferiority is a better level of evidence than demonstrating no proof of difference. Our purpose was to re-analyze the data on systemic safety published in these two meta-analyses by application of a non-inferiority design. According to our results, we extended this finding by demonstrating that bevacizumab is non-inferior in safety compared with ranibizumab.

Link PubMed del paper
https://pubmed.ncbi.nlm.nih.gov/30369396/